Bill Clarke
Profile
Bill Clarke served as President & Chief Executive Officer at Cellectar, Inc. and as Chairman at Caden Biosciences, Inc. He also held positions as Director at Glaxo Wellcome Plc, VisualSonics, Inc., and Axela, Inc., and as Independent Director at Brio Device LLC.
Prior to his industry career, he was an Associate Professor at the University of Washington.
Clarke's education includes undergraduate, graduate, and doctorate degrees from Duke University.
Former positions of Bill Clarke
Companies | Position | End |
---|---|---|
Cellectar, Inc.
Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Chief Executive Officer | 2010-07-31 |
Caden Biosciences, Inc.
Caden Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Caden Biosciences, Inc. develops assays for G-protein coupled receptors. It serves the pharmaceutical industries. The company was founded in 2000 and is headquartered in Madison, WI. | Chairman | 2009-09-09 |
Brio Device LLC
Brio Device LLC Medical SpecialtiesHealth Technology Brio Device LLC operates as a medical device company which creates solutions for endotracheal intubation that enables clinicians and first responders to manage airways. It specializes in the R&D and sales and marketing of their airway management devices. The company was founded by Douglas Mullen, Laura McCormick, Sabina Siddiqui and Hannah Hensel in 2011 and is headquartered in Ann Arbor, MI. | Director/Board Member | - |
University of Washington
University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Glaxo Wellcome Plc | Chief Tech/Sci/R&D Officer | 2010-05-12 |
Training of Bill Clarke
Duke University | Doctorate Degree |
Experiences
Positions held
Linked companies
Private companies | 8 |
---|---|
Axela, Inc.
Axela, Inc. Medical SpecialtiesHealth Technology Axela, Inc. develops biosensor technology. It offers next generation, commercial stage, multiplex tools that provide enhanced analysis of proteins, DNA and RNA. The firm’s products include Ziplex System, autograph, metabolic, colon and breast cancer, inflammation Xpress chips, diffractive optics technology and sensors, dotLab mX System and dot-Avidin, Ready and Covalent products. The company was founded by M. Cynthia Goh, Richard Loo, B. Jane Goh and Richard McAloney in 2001 and is headquartered in Toronto, Canada. | Health Technology |
VisualSonics, Inc.
VisualSonics, Inc. Medical SpecialtiesHealth Technology VisualSonics, Inc. developed vivo imaging systems for non-invasive small animal research. The company was founded by F. Stuart Foster in 1999 and headquartered in Toronto, Canada. | Health Technology |
Cellectar, Inc.
Cellectar, Inc. Miscellaneous Commercial ServicesCommercial Services Cellectar, Inc. is a clinical stage radiopharmaceutical company that designs and develops products to detect, treat and monitor a wide variety of human cancers. Cellectar began independent lab activities in February 2003 after forming a company and raising initial funds in the 2000-2002 timeframe. Its product candidates combine phospholipids ethers analogs (PLEs), which are lipid-like molecules, with radioisotopes that destroy or image malignant cancer cells. Because only malignant tumor cells and tissues retain large amounts of these compounds, malignant cancer-selective retention of therapeutic or diagnostic doses of radioactivity can be achieved. Cellectar has demonstrated specific uptake and retention of its product candidates in more than 45 tumor types tested in proof-of-principle preclinical animal studies. In addition, ten preclinical experiments have shown anti-tumor activity in each tumor type studied including breast, prostate, lung, glioma, pancreatic, melanoma, ovarian, uterine, renal and colorectal cancers. The compound, originally known as NM404, is being taken through the regulatory process as CLR1404. Capitalizing on the unique characteristics of malignant cancer cells, Cellectar's molecules will be designed to find, treat and follow malignancies through the delivery of radiopharmaceuticals in a novel, highly selective way. | Commercial Services |
Caden Biosciences, Inc.
Caden Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Caden Biosciences, Inc. develops assays for G-protein coupled receptors. It serves the pharmaceutical industries. The company was founded in 2000 and is headquartered in Madison, WI. | Health Technology |
GE Healthcare Ltd. (United Kingdom)
GE Healthcare Ltd. (United Kingdom) Medical SpecialtiesHealth Technology GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom. | Health Technology |
Amersham Health | |
Glaxo Wellcome Plc | Health Technology |
Brio Device LLC
Brio Device LLC Medical SpecialtiesHealth Technology Brio Device LLC operates as a medical device company which creates solutions for endotracheal intubation that enables clinicians and first responders to manage airways. It specializes in the R&D and sales and marketing of their airway management devices. The company was founded by Douglas Mullen, Laura McCormick, Sabina Siddiqui and Hannah Hensel in 2011 and is headquartered in Ann Arbor, MI. | Health Technology |
- Stock Market
- Insiders
- Bill Clarke